Oncology First Strategy Enables Clinical OS
Caroline Zhang, CEO of Knowtex, on going from AI medical scribe to AI lab
Starting in oncology was a product strategy to build a harder to copy engine, not just a first use case. Oncology visits force the system to handle dense medication vocabularies, long treatment histories, side effects, comorbidities, and trial eligibility in one note and order workflow. Knowtex then reuses that specialty training and workflow logic across more than 200 specialties, turning one hard wedge into broader health system expansion.1 2 3 4
- Knowtex did not stop at note drafting. In oncology deployments it bundles note taking, coding, ordering, chart prep, and trial and drug guidance, which matters because an oncologist visit often ends with labs, infusion plans, and follow up actions that have to be captured correctly in the EHR.1 3 4 5
- This is a different path from lighter weight ambient scribes. Abridge built deep traction by embedding directly inside Epic note workflows across large health systems, while Ambience emphasizes specialty tailored documentation and coding. Knowtex is pushing further into the specialty workflow itself, especially in oncology clinics.2 6 7
- The payoff is sales leverage with complex enterprise buyers. Knowtex says it supports over 200 specialties, and its oncology roots have already led to cancer care partnerships like cCARE and PCSRI. That makes it easier to sell into multispecialty groups and service lines that want one vendor across many clinician workflows.1 3 8 9
The category is moving from ambient note capture into full clinical operating software. The winners are likely to be the companies that can turn one conversation into a finished note, coded visit, drafted orders, and next step guidance inside the EHR. Starting in oncology gave Knowtex a training ground for exactly that broader workflow shift.1 2 4 5 6